We create breakthrough products – in diagnostics, medical devices, nutrition and branded generic pharmaceuticals – that help you, your family and your community lead healthier lives, full of unlimited possibilities. Today, 103,000 of us are working to
Chicago, Illinois, United States
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Abbott posts 12% revenue drop amid baby formula disruption, waning COVID impact
- Abbott Laboratories Non-GAAP EPS of $1.03 beats by $0.10, revenue of $10.1B beats by $410M
- Abbott Q4 results in focus as DOJ probe on baby formula plant looms
- Abbott under DOJ criminal probe over behavior at Michigan baby formula plant - WSJ
- Catalyst watch: Tesla reverberations, Intel earnings, Rocket Lab launch and Macau stocks on holiday
- Abbott receives FDA approval for transcatheter aortic valve implantation system
- COVID-19 public health emergency extended by HHS, possibly for final time
- WHO sets Jan. 27 meeting to decide on COVID emergency
- CES 2023: What's happening at the Consumer Electronics Show?
- Wynn Resorts and Merck among Wells Fargo's conviction calls for Q1
- Diabetes rates in children set to skyrocket by 2060 - study
- Imported baby formula to face US tariffs again in 2023 - WSJ
- Goldman Sachs highlights key healthcare themes for 2023
- Abbott wins FDA approval of Eterna spinal cord stimulation system
- White House restarts program to ship free at-home COVID tests
- WHO chief hopeful COVID emergency will end next year
- Abbott Laboratories raises quarterly dividend by 8.5% to $0.51/share
- EU wants to delay medical device law amid supply challenges - Reuters
- Reckitt thinks U.S. baby formula shortage will persist until spring – Reuters
- World Health Organization renames monkeypox as mpox